As an extension of previous work, a microfluidic device, which can separate blood plasma in a continuous, real-time fashion from a whole blood, is successfully integrated with a mock cardiopulmonary bypass circuit. The functionality of the device is demonstrated with the use of freshly harvested bovine blood. The plasma selectivities were 100% and 99.4% and the plasma separation volume percents were 18.7% and 24.5% for 26% and 37% inlet hematocrit levels, respectively. As an advanced stage of this research, a microfluidic device, which can measure the concentration of clinically relevant blood plasma protein in a continuous fashion, is being developed on the basis of fluid handling circuits coupled to fluorescent cytometric bead assays. The functionality of the device is demonstrated with the use of a biotinylated FITC solution and a streptavidin-coated, 8-m-diameter bead. The binding event between biotinylated FITC and the streptavidin bead is continuously detected within a detection window at the outlet of the device. For a known concentration (1 g/ml) of biotinylated FITC solution, the measured fluorescent intensity is fairly constant and shows a stable gaussian distribution of the bead fluorescence intensity. It is expected that the proposed device can be used for continuous measurement of clinically relevant proteins during cardiac surgery with the cardiopulmonary bypass procedure. ASAIO Journal 2006; 52:698-704.
It has been well documented [1] [2] [3] [4] [5] [6] [7] [8] [9] that cardiopulmonary bypass (CPB) procedures significantly affect systemic inflammatory responses of patients during cardiac surgery. Currently, there is no effective medical intervention or method for preventing this systemic inflammatory response. Therefore, there is an unmet medical need to develop safe and effective therapeutic diagnostics to monitor this inflammatory response in real time, while the surgery is proceeding, to better understand how CPB and surgical or anesthetic procedures might be modified to prevent its occurrence. Current technology provides measurements of the effects of CPB on activation of complements, neutrophils, platelets, and cytokines hours or days after surgery. More immediate measurements would aid in understanding the mechanisms of cellular activation and modify surgical and perfusion protocols for minimizing the adverse effects of cardiopulmonary bypass.
To accomplish immediate measurements of the clinically relevant proteins, such as cytokines and complements, two functions must be obtained in a continuous, real-time fashion: blood plasma separation and detection of proteins. This research designed a microanalytical system for online monitoring of inflammatory responses. It includes a plasma autoseparation device and a novel micro-immunoassay (IA) for continuous measurements. As demonstrated in previous reports, 10, 11 purified blood plasma can be collected in continuous, real-time fashion within a microfluidic channel, using the Zweifach-Fung effect. 12, 13 In this report, the integration of the continuous, real-time blood plasma separation device with a CPB circuit is demonstrated with the use of the previously designed blood plasma separation device. As a second stage of this research, a microfluidic device, which is designed to monitor clinically relevant proteins in a continuous fashion, is demonstrated, using biotinylated FITC dye and streptavidincoated, 8-m-size beads.
Materials and Methods

Experimental Setup
The microfluidic devices have been fabricated in polydimethylsiloxane (PDMS), using the conventional soft lithography process. 14, 15 In soft lithography, a master mold is first made by standard lithographic patterning of a silicon wafer, using Shipley 1818 photoresist (Shipley Company, L.L.C., Marlborough, MA), followed by silicon deep reactive ion etching (DRIE) to a depth of 10 m to form a negative imprint of the channels on a silicon wafer. Next, PDMS is cast from this master silicon mold to obtain a positive pattern. After forming a positive PDMS structure, the PDMS microchannels are plasma-activated and bonded to another piece of PDMS to form a closed capillary structure. For the integration of the blood plasma separation device with an extracorporeal circuit, the device was mounted on an inverted microscope for visualization. The extracorporeal circuit consisted of a heart-lung machine (Jostra HL-20, Maquet, Inc., Bridgewater, NJ), a low-prime, hollow-fiber membrane oxygenator (Capiox baby-RX, Terumo Corp., To-kyo, Japan), an arterial filter (Capiox), and quarter-inch arterial and venous tubing. The extracorporeal circuit was primed with fresh bovine blood and lactated Ringer's solution. Fresh bovine blood was collected from the jugular vein through a catheter in a heparinized blood bag; it was hemodiluted to 37% or 26% hematocrit with lactated Ringer's solution. The inlet of the separation device was connected to the arterial port of the membrane oxygenator, as shown in Figure 1 .
In all experiments, the flow rate of CPB pump was fixed at 500 ml/min and the blood was fed into the device from the pressure head generated from the pump head at an estimated flow rate of 3 l/min. The blood cells in the microchannels were imaged by using a high-resolution (1376 ϫ 1040 pixel) CCD Camera (Cooke SensiCam QE, Romulus, MI) at a frame rate of 10 frames/s and variable shutter time. After obtaining images, they were analyzed with the use of an image processor program called "Hemocytometer" 10 to obtain the hematocrit change between upstream and downstream of the separation region as well as the particle motion at the bifurcation.
For the demonstration of continuous sensing experiments, commercially available 8-m-diameter, streptavidin-coated beads (Bangs Laboratories, Inc., Fishers, IN) and biotinylated-FITC (Fluorescein Isothiocyanate) dye (Invitrogen, Carlsbad, CA) were used. The streptavidin-coated beads in the microchannels were also imaged by using the high-resolution CCD camera (1376 ϫ 1040 pixels) with two different shutter open conditions. For capturing bead motion, the shutter was allowed to remain open for 20 s/frame. For investigating the flow patterns, 100-ms/frame was maintained to obtain a fluorescent image of the flow pattern. After obtaining each image, they were overlayed to obtain a final image, which shows both the fluorescent flow pattern and bead motion within the microchannel. The fluorescent intensity at the detection window was analyzed by means of a novel image processor program named "IA (micro-Immunoassay)." prepared by LabVIEW 7.0 (National Instruments Inc., Austin, TX). Fresh bovine blood hemodiluted to 37% or 26% hematocrit was introduced into the separation device from the CPB pump by connecting the inlet of the separation device to the arterial port of the membrane oxygenator. Flow rate of the CPB pump was 500 ml/min for this study.
Results
Integration of the Continuous, Real-Time Blood Plasma Separation Microfluidic Device With CPB Circuit
The principle of the plasma separation device is based on the bifurcation law, also called the Zweifach-Fung effect. The demonstration of Zweifach-Fung effect in the microfluidic channel and the bench top performance of the blood plasmas separation device are well documented in previous reports. 10, 11 Briefly, the bifurcation law describes that in the microcirculation, when erythrocytes (red blood cells) flow through a bifurcating region of a capillary blood vessel, they have a tendency to travel into the daughter vessel, which has the higher flow rate, leaving very few cells flowing into the lower flow rate vessel. The critical flow rate ratio between the daughter vessels for this cell separation is approximately 2.5:1 when the cell-to-vessel diameter ratio is of the order of one. Devices were previously designed on the basis of this principle and in laboratory experiments successfully demonstrated the ability to separate blood cells from plasma and to recover a significant percentage of the total plasma volume out of the total infused fluid volume. 10, 11 To observe individual blood cell dynamics, images were acquired by using a higher resolution (1376 ϫ 1040 pixels) CCD camera with a shorter shutter speed (20 s/frame) at x20 magnification. Figure 2 shows representative photographs of continuous, real-time blood plasma separation within a device coupled to an extracorporeal circuit for 26% inlet hematocrit (a) and 37% inlet hematocrit (b). During a total of 1 hour of continuous blood infusion through a mock CPB machine at 26% of inlet hematocrit, no cells traveled into the plasma channels. However, for 37% inlet hematocrit, a few cells traveled into the plasma channels, probably as the result of individual cell bombardments that push a cell into the side plasma channels. These results are similar to those obtained from the bench top experiments 10, 11 and experimentally demonstrate that continuous, real-time blood plasma separation could be accomplished during cardiac surgery with the CPB procedure.
A Microfluidic Device for Continuous Measurement of Clinically Relevant Proteins
The operating principle of the device is based on a mechanism named "the particle cross over method." Figure 3 shows a schematic diagram of the particle cross-over method. When a micronsized bead approaches a bifurcation, it is possible for the bead to cross over from one fluid stream into another by controlling flow rate ratio of the two downstream channels without mixing of two fluid environments. For example, a streptavidin-coated bead in Figure 3 . Schematic diagram of a microfluidic device for a continuous measurement of biotin-streptavidin binding event, using the particle cross-over mechanism. Figure 4 . a, Schematic diagram of a microfluidic device for continuous sensing of biotin-streptavidin binding event. Dashed area is zoomed in (b). b, Each bifurcation is composed of eight sub-bifurcation channels, which are parallel to each other. At each subbifurcation, 11-to-1 flow rate is maintained to make sure that no streptavidin-coated beads enter into parallel channel (carrier solution outlet) while only carrier fluid travels into these channels. buffer media can cross over to the biotinylated FITC solution without mixing two fluids by precisely controlling flow rate ratio to be 1:1 between the two daughter channels. By utilizing this effect, the binding between biotinylated FITC molecule and the streptavidin-coated bead could be achieved within the channel without mixing of the two fluids at the 1 st bifurcation. In addition, there is no serial dilution effect on the analyte of interest, as would be expected by simply mixing the fluids together through a converging channel geometry. At the 2 nd bifurcation, the biotinylated FITC-bound streptavidin bead can then cross over to a wash solution without any background fluorescence from the FITC dye in solution.
To avoid bead movement toward the outlets at each bifurcation, multiple parallel branch channels, which have an optimal flow rate ratio between main channel and individual branch channels, are placed. Figure 4 shows a schematic diagram of a microfluidic device for the continuous sensing of a biotin-streptavidin binding event (a). The device is composed of three inlets and three outlets to feed appropriate media into the device and to precisely control the flow rate ratio at each bifurcation. Each bifurcation region is composed of 8 subbifurcations to avoid streptavidin coated bead loss by incorporation to parallel outlet channels (b). At each sub-bifurcation, an 11-to-1 flow rate ratio is maintained to ensure no bead loss and no mixing between two fluids.
To avoid the loss of the streptavidin bead toward parallel channels (outlets) while carrier fluid is removed toward parallel channels, each bifurcation is carefully designed by using various design techniques, including an analogous electrical circuit, analytical studies, as well as numerical studies. 10, 11 Each bifurcation is designed to have a total of 1:1 flow rate ratio between main and parallel channels. An 11-to-1 flow rate ratio at each sub-bifurcation is maintained between main and individual parallel channels to ensure that no beads travel into the parallel channel. Figure 5 shows micrographs of the streptavidin-coated bead motion at each bifurcation region. The flow rate at all inlets was fixed at 10 l/h. At 1 st bifurcation (1st), the streptavidin-coated bead is approaching the bifurcation region (1 st -1). The welldeveloped flow patterns of biotinylated FITC solution and the Figure 5 . At each bifurcation, streptavidin-coated beads cross over from one to another fluid without any mixing of two fluids (1 st ). A streptavidin-coated bead enters a biotinylated FITC solution without mixing between biotinylated FITC and bead carrier solutions. Since the flow rate ratio at each sub-bifurcation is maintained at 11 to 1, the bead can cross over from one to another solution. Once the bead enters into the biotinylated FITC solution, the binding event between biotinylated FITC and the streptavidin-coated bead occurs (2 nd ). After binding with the biotin-FITC, a streptavidin bead leaves the solution for fluorescence quantification. streptavidin-coated bead carrier solution are shown. No significant diffusion between two fluids at the carrier-dye interface is seen. Because of the properly defined flow rate ratio (11 to 1) at each sub-bifurcation, the streptavidin-coated bead crosses over into the biotinylated FITC solution without flowing into the parallel channels (outlet). Once the streptavidin-coated bead enters into the biotinylated FITC solution, the binding between the biotinylated FITC dye molecule and streptavidin coating on the bead occurs. It is assumed that the biotin-avidin binding events are proportional to the concentration of the biotinylated FITC dye. Thus, at the detection window, the measured bead fluorescence intensity should be proportional to the concentration of the biotinylated FITC concentration. At 2 nd bifurcation, the biotinylated FITC-conjugated, streptavidin-coated bead crosses over into the first washing solution I (PBS, phosphate buffered saline, for this study). Again, as shown in (2 nd ), the flow pattern is well developed and a clear boundary between two fluids is seen without significant mixing between. By passing the bifurcation region, the biotinylated FITC-conjugated streptavidin bead enters into the washing solution I (2 nd -2 and 2 nd -3) and thus there is minimal background fluorescent intensity (noise) within the surrounding fluid, and a maximum signal-to-noise ratio on the measured bead fluorescence is expected. Throughout the study, no beads entered the parallel channels (outlets), implying that the 11-to-1 flow rate ratio at each sub-bifurcation secures all beads within the main channel.
Discussion
Integration of the Continuous, Real-Time Blood Plasma Separation Microfluidic Device With CPB Circuit
The device performance was determined by calculating the plasma selectivity () and the total plasma separation volume percent out of total plasma volume (). These are defined 10 as
(2) where H p is a hematocrit level at the plasma channels, H mu and Figure 6 . Hematocrit histograms obtained from image processing of 210 images for (a) 26% inlet hematocrit and (b) 37% inlet hematocrit. In both cases, there is a shift in hematocrit between upstream (H mu ) and downstream (H md ) of the bifurcation, where is the plasma selectivity and is the plasma separation volume percent of total plasma volume. Figure 7 . Biotinylated FITC conjugated streptavidin bead motion at the detection window. Due to dynamic binding and washing at the upstream portion of the device (see Figure 5 ) without mixing of reagent solution (Biotinylated FITC) and wash solution (PBS), the bead is generating background free fluorescence. The fluorescence intensity of the bead is assumed to be proportional to the concentration of the Biotinylated FITC. Dashed box represents a region of interest for intensity measurement.
H md are hematocrit levels at upstream and downstream of the main channel, respectively. The hematocrit levels at each region of interest (Figure 2) are obtained by using the previously prepared "hemocytometer" program. 10 Figure 6 shows hematocrit histograms obtained from image processing of 210 consecutive images for (a) 26% inlet hematocrit and (b) 37% inlet hematocrit levels. First, it should be noted that the measured hematocrit levels (6.6%, 10.4%) upstream of the separation region is much lower than the infused hematocrit (26%, 37%, respectively). This is due to the Fahraeus effect, 16 which has documented that when blood of a constant hematocrit flows from a large feed inlet into a small channel, the average hematocrit in the channel decreases as the channel diameter decreases. This has also been previously observed within the plasma separation device. 10 In both cases, there are statistically significant (p Ͻ 0.05) shifts in hematocrit levels between upstream and downstream of the bifurcation region. Plasma selectivity of 100% and 99.41% were obtained for 26% and 37% inlet hematocrit levels. The plasma separation volume percents out of the total infused plasma volume are 18.76% and 24.5% for 26% and 37% inlet hematocrit levels, respectively. A higher inlet hematocrit level (H in ) produces a higher upstream hematocrit level (H mu ). As a result, a higher downstream hematocrit level (H md ) is produced. Since the plasma separation volume percent is represented by the difference between H mu and H md , as described in Equation 2, a larger upstream hematocrit produces the larger plasma separation volume percent. These performances of the device are similar to those obtained from the bench-top test previously reported. 10 Therefore, it is clear that the blood plasma separation device studied here may be used in cardiac surgery with CPB procedures to collect blood plasma in continuous, real-time fashion.
A Microfluidic Device for Continuous Measurement of Clinically Relevant Proteins
Once the bead motion and the flow pattern at each bifurcation were studied, the stability of the device was evaluated by measuring fluorescent intensity of the bead at the detection window. In this study, the concentration of the biotinylated FITC solution was fixed at 1 g/ml, and the flow rate of all inlets were also fixed at 10 l/h. Figure 7 shows a series of fluorescent images of the bead motion at the detection window. The dashed box guides the region of interest for the measurement of fluorescent intensity of the bead. Due to dynamic binding and washing processes at the upstream of the device without mixing of reagent solution (Biotinylated FITC) and washing solutions (PBS), the biotinylated FITC conjugated streptavidin bead generates very bright and background noise free fluorescence. In the measurement of fluorescent intensity of the bead, a program called "IA, micro-Immunoassay" was used to quantify fluorescent intensities of the beads. To extract pure pixel intensities of each bead, a series of background images were taken and processed to obtain maximum background pixel intensities of each pixel. Once the maximum background pixel intensities were obtained, then the pixel intensities of each pixel of the bead were subtracted by the maximum intensities obtained from background pixel intensity analysis to acquire pure pixel intensities of the bead. The pixel intensities of each bead were statistically assumed to have a gaussian distribution. The mean and standard deviation of the bead pixel intensities were obtained by conducting gaussian fitting on the raw distribution. Figure 8 shows a histogram of fluorescent intensities obtained from the analysis of 339 beads at the detection window and its gaussian distribution for concentration of 1 g/ml. The mean and standard deviation of the bead pixel intensities are 43.52 and 19.39, respectively. And the distribution of the bead pixel intensities is well fit with gaussian distribution. Therefore, the particle cross over mechanism introduced in this report is a very useful mechanism for the application of continuous sensing of biomarkers such as complement, cytokines, although further investigations are required to quantify the device's performance more precisely.
Conclusion
A microfluidic device for continuous, real-time blood plasma separation was successfully integrated with a mock CPB machine. The performance of the device was demonstrated using bovine blood and was similar to results obtained from bench top laboratory testing. Regardless of the inlet hematocrit levels, the plasma selectivity was almost 100%. The plasma separation volume percents of total plasma volume were 18.76% and 24.5% for 26% and 37% inlet hematocrit levels, respectively.
The "particle cross-over method" from one fluid stream to another was successfully demonstrated using biotinylated FITC dye and streptavidin coated 8-m-sized beads. The bead can cross over from one fluid (e.g., bead carrier fluid) to another (e.g., biotinylated FITC solution) without significant mixing of two fluid streams. The fluorescent intensities of the streptavidin beads after biotin-avidin binding have shown gaussian distribution. For 1 g/ml of biotinylated FITC, the mean and standard deviation of the bead pixel intensities are 43.52 and 19.39, respectively. Future work will be conducted to optimize binding kinetics and residence times to maximize bead fluorescence signals and increase mean pixel intensity and obtain lower standard deviations within the measured bead populations. The device will then be tested at a variety of biotin concentrations. Future work will also include quantifications of the developed -immunoassay device. These will include the relation between the known concentrations of the reagents (biotin, complements, and cytokines) and fluorescent intensities. Since, the fluorescent intensity of the bead is a function of the concentration of the biotinylated FITC and the resident time of the bead in the reagent channel (biotinylated FITC), the effect of these will be investigated. Also, the device's performance with respect to varying concentration of reagents will be investigated to generate a calibration curve of bead fluorescence intensity versus biotin concentration and lower concentration detection levels. Other approaches to improving fluorescence signals are to use laser excitation to improve fluorescence intensity and photomultiplier tube detection to improve fluorescence detection. As a final stage of the research, the plasma separation device and the -immunoassay device will be integrated together by redesigning two devices to obtain full functions (separation, detection) on a single chip. Because of the simple operating principle and structure of the devices, these devices are very promising to be used for continuous, real time separation and detection of clinically relevant proteins such cytokines, complements. These devices are expected to allow studies of the development of systemic inflammation in real-time during CPB procedures.
